Actively Recruiting
Proteinopathies Expression in Skin of Neurodegenerative Disorders
Led by Universidad Autonoma de San Luis Potosí · Updated on 2024-12-16
40
Participants Needed
1
Research Sites
149 weeks
Total Duration
On this page
Sponsors
U
Universidad Autonoma de San Luis Potosí
Lead Sponsor
H
Hospital Central "Dr. Ignacio Morones Prieto"
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 \[TDP43\]) in skin biopsies of patients with a neurodegenerative disease like Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus. The main question it aims to answer is: * Is there a specific pattern of aggregation of proteinopathies in skin biopsies in each neurodegenerative disease in comparison to healthy control subjects? Skin biopsies will be analyzed using immunohistochemistry and immunofluorescence for detection of alpha-synuclein, amyloid-beta, phosphorylated tau and TAR DNA binding protein 43, and the aggregation patterns will be compared between patients with a neurodegenerative disease vs patient with normal pressure hydrocephalus vs healthy control subjects.
CONDITIONS
Official Title
Proteinopathies Expression in Skin of Neurodegenerative Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 45 years and older
- Men and women
- Diagnosed with Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis, or normal pressure hydrocephalus
- Voluntarily agree to participate and sign consent form
- Healthy controls aged 45 years and older
- Healthy controls can be related to patients but not by blood
- Healthy controls have no direct family history of neurodegenerative disease
- Healthy controls have no clinical signs of dementia
- Healthy controls voluntarily agree to participate and sign consent form
You will not qualify if you...
- Personal history of cerebrovascular disease, psychiatric disease, post traumatic dementia, or HIV related dementia
- Unclear or unconfirmed diagnosis
- Presence of neuroinfection
- Diagnosed skin disease
- "Atypical" presentation of the neurodegenerative disease
- Diagnosis of a coagulopathy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Central Dr. Ignacio Morones Prieto
San Luis Potosí City, Mexico, 78290
Actively Recruiting
Research Team
I
Ildefonso Rodríguez-Leyva, MD PhD
CONTACT
C
Cristina Monzón Tapia, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here